Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial.

Shao YF, Yang JM, Chau GY, et al.
Am J Surg 2006;191(2):245-249.
NATA Rating :
Review by : M. Aldouri
NATA Review

This is another randomized study on the use of rFVIIa in patients with chronic liver disease undergoing liver surgery, but the dose of rFVIIa was given more frequently than in previously published data. There was no statistical difference in amount of red cell transfusion between the treatment and placebo groups, probably because most of the patients had early cirrhosis and therefore did not have severe coagulopathy. The incidence of adverse effects was similar in the three groups.

– Maadh Aldouri

Consent Management Platform by Real Cookie Banner